Business Context and Reporting Period
Company: electroCore, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 19, 2021
Reporting Period: Single event date (January 19, 2021)
electroCore, Inc. is a Delaware corporation trading on the NASDAQ Global Select Market under the symbol ECOR. The company is designated as an emerging growth company.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material event reported is the establishment of a unique Level II HCPCS code by the Centers for Medicare and Medicaid Services (CMS). Specifically, code K1020, titled "Non-invasive vagus nerve stimulator," was created to cover the Company's gammaCore Sapphire D device.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the CMS code assignment but does not include forward-looking guidance, financial outlook, or specific risk factors within the body of this report.
Unusual Items: The assignment of a specific reimbursement code is a significant regulatory milestone for the company's product line.
Investor Verification Checklist
- Verify the effective date and specific reimbursement details of HCPCS code K1020 via the CMS database.
- Review the full text of the press release filed as Exhibit 99.1 for additional context on the gammaCore Sapphire D.
- Confirm the impact of this code on the company's revenue recognition and sales strategy in subsequent quarterly reports (10-Q/10-K).
- Check for any state-level Medicaid adoption of this new code, as federal CMS codes do not automatically guarantee state reimbursement.